Featured Research

from universities, journals, and other organizations

Molecular switch suppresses development of liver cancer

Date:
October 21, 2013
Source:
National University of Singapore
Summary:
Findings by researchers contribute towards the development and application of therapeutics for liver cancer.

A team of scientists from the National University of Singapore (NUS) has found that activating a family of small protein, known as Rho, could suppress liver malignancies. This is the first time that a research group has provided evidence to show that the signaling crosstalk between different protein switches has an influence on the development of cancer tissues. The findings pave the way for the development and application of therapeutics targeted at liver cancer.

The team, led by Associate Professor Low Boon Chuan from the Department of Biological Sciences at the NUS Faculty of Science and the Mechanobiology Institute at NUS, first published the research in the journal Oncogene.

Importance of signalling crosstalk between proteins

The proteins Ras and Rho are among the key molecular switches that control cell dynamics, cell growth and tissue development through their distinct signalling pathways. Although much has been studied about their individual functions, the underlying molecular mechanism of signalling crosstalk between these two proteins in an in vivo context remains largely unknown, especially in the area of liver development and formation of liver tumours.

In order to identify the consequences of their signalling crosstalk, the research team generated different scenarios with different liver-specific proteins and genes that have the potential to cause cancer, using the zebrafish as an in vivo model.

Due to its ability to reverse and forward genetics and low incidence of spontaneous tumours, the zebrafish is fast becoming a popular model for studying human cancers.

Through the use of quantitative bioimaging and molecular markers, the team found that when the zebrafish is induced to produce an active state of Kras (a form of Ras), which is an oncogene, liver enlargement is observed, and liver cancer that resembles the human liver cancer was formed. Subsequently, in adult zebrafish, the hepatocellular carcinoma, a major form of liver cancer, was developed. However, when the same cells were made to turn on Rho, these abnormalities were abated.

The team also found that when an inactive form of Rho was introduced when Kras is kept active, the Kras-mediated liver overgrowth and tumour formation were elevated.

These findings provided evidence about the significance of the previously understudied signalling crosstalk between the proteins Kras and Rho in regulating liver overgrowth, transformation of liver tissue and cancer mortality. As Rho is a known inducer of mechanical force, the team’s findings also implicate the possible role of mechanical and physical forces in regulating cancer development and other functions in the liver.

The Next Step

The group is now investigating the exact chain of biochemical reactions that specify such unique signalling crosstalk. They are also investigating the aspects of cell metabolism and other major growth related pathways that are being affected to address the inherent inconsistency associated with cell-based studies. They hope to establish zebrafish as an alternative drug screening platform that is relatively cheap and convenient to identify novel targets for therapeutic intervention.


Story Source:

The above story is based on materials provided by National University of Singapore. Note: Materials may be edited for content and length.


Cite This Page:

National University of Singapore. "Molecular switch suppresses development of liver cancer." ScienceDaily. ScienceDaily, 21 October 2013. <www.sciencedaily.com/releases/2013/10/131021094119.htm>.
National University of Singapore. (2013, October 21). Molecular switch suppresses development of liver cancer. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2013/10/131021094119.htm
National University of Singapore. "Molecular switch suppresses development of liver cancer." ScienceDaily. www.sciencedaily.com/releases/2013/10/131021094119.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins